{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:40:20Z","timestamp":1770813620583,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Oral anticancer agents (OAAs) are commonly prescribed for patients with primary brain tumors, but adherence can be challenging due to cognitive impairment and discontinuous treatment schedules. This subgroup analysis of the randomized phase 3 CAPRI trial evaluated the impact of a nurse navigator-led intervention combined with a digital platform (web portal and mobile app) versus standard care in patients with primary brain tumors treated with OAAs. The primary endpoint was Relative Dose Intensity (RDI), with secondary endpoints including adherence, toxicity, healthcare utilization, and patient-reported experience. Fifty-one patients were included between October 2016 and May 2019, 63% of whom had glioblastoma. Twenty-six patients received the intervention. RDI was significantly higher in the intervention group compared to the control group (105%\u2009\u00b1\u200912 vs. 97.6%\u2009\u00b1\u200913,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). The intervention also resulted in fewer emergency room visits, reduced hospitalizations, greater use of supportive care services, and improved patient-reported experience (all\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Remote monitoring allowed early corticosteroid adjustments in cases suggestive of intracranial hypertension, helping to prevent hospitalizations. No significant differences were observed in treatment-related toxicity. These findings suggest that a nurse navigator-led digital intervention can improve care continuity and outcomes in this population and merit further investigation.\n                  <\/jats:p>","DOI":"10.1038\/s41746-025-02325-3","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:04:40Z","timestamp":1768457080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of nurse navigation and mobile app on brain tumor patients receiving oral anticancer therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Caroline","family":"Poisson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeline","family":"Duflot-Boukobza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Mathivon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Khettab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ferrua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Fourcade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na\u00efma","family":"Lezghed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Dhermain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Lemare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Minvielle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Guyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah N.","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"2325_CR1","unstructured":"Tamimi, A. F. & Juweid, M. Epidemiology and outcome of glioblastoma. In Glioblastoma (ed. De Vleeschouwer, S.) (Codon Publications, 2017)."},{"key":"2325_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2325_CR3","doi-asserted-by":"publisher","first-page":"v194","DOI":"10.1093\/neuonc\/nov230.27","volume":"17","author":"H Zwinkels","year":"2015","unstructured":"Zwinkels, H. et al. QOL-27 Prevalence of changes in personality and behavior in adult glioma patients : a systematic review. Neuro Oncol. 17, v194 (2015).","journal-title":"Neuro Oncol."},{"key":"2325_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1212\/WNL.0000000000000671","volume":"83","author":"S Kerrigan","year":"2014","unstructured":"Kerrigan, S., Erridge, S., Liaquat, I., Graham, C. & Grant, R. Mental incapacity in patients undergoing neuro-oncologic treatment. Neurology 83, 537\u2013541 (2014).","journal-title":"Neurology"},{"key":"2325_CR5","doi-asserted-by":"crossref","unstructured":"Alencar, B. S. X. D., Macedo, B. S. P., Teraoka, E. C., Santos, A. J. & Domenico, E. B. L. D. ADES\u00c3O \u00c0 QUIMIOTERAPIA ANTINEOPL\u00c1SICA ORAL, APOIO SOCIAL E BEM-ESTAR DE PACIENTES COM C\u00c2NCER CEREBRAL: ESTUDO CORRELACIONAL. Rev. Baiana Enferm. 37, https:\/\/periodicos.ufba.br\/index.php\/enfermagem\/article\/view\/51209 (2023).","DOI":"10.18471\/rbe.v37.51209"},{"key":"2325_CR6","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1200\/JOP.2012.000834","volume":"9","author":"RM Morrell","year":"2013","unstructured":"Morrell, R. M. et al. An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. J. Oncol. Pract. 9, e268\u2013e271 (2013).","journal-title":"J. Oncol. Pract."},{"key":"2325_CR7","first-page":"831","volume":"28","author":"A Vyas","year":"2022","unstructured":"Vyas, A. et al. Predictors of adherence to oral anticancer medications: an analysis of 2010-2018 US nationwide claims. J. Manag. Care Spec. Pharm. 28, 831\u2013844 (2022).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"2325_CR8","first-page":"156","volume":"18","author":"L McCann","year":"2009","unstructured":"McCann, L., Maguire, R., Miller, M. & Kearney, N. Patients\u2019 perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur. J. Cancer Care 18, 156\u2013164 (2009).","journal-title":"Eur. J. Cancer Care"},{"key":"2325_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.soncn.2011.02.005","volume":"27","author":"SM Schneider","year":"2011","unstructured":"Schneider, S. M., Hess, K. & Gosselin, T. Interventions to promote adherence with oral agents. Semin. Oncol. Nurs. 27, 133\u2013141 (2011).","journal-title":"Semin. Oncol. Nurs."},{"key":"2325_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","volume":"28","author":"O Mir","year":"2022","unstructured":"Mir, O. et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat. Med. 28, 1224\u20131231 (2022).","journal-title":"Nat. Med."},{"key":"2325_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/01.mlr.0000160375.47920.8c","volume":"43","author":"RE Glasgow","year":"2005","unstructured":"Glasgow, R. E. et al. Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med. Care 43, 436\u2013444 (2005).","journal-title":"Med. Care"},{"key":"2325_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky, D. E., Green, L. W. & Levine, D. M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care 24, 67\u201374 (1986).","journal-title":"Med. Care"},{"key":"2325_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1056\/NEJMoa1000678","volume":"363","author":"JS Temel","year":"2010","unstructured":"Temel, J. S. et al. Early palliative care for patients with metastatic non\u2013small-cell lung cancer. N. Engl. J. Med. 363, 733\u2013742 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2325_CR14","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","volume":"31","author":"E Basch","year":"2025","unstructured":"Basch, E. et al. Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. Nat. Med. 31, 1225\u20131232 (2025).","journal-title":"Nat. Med."},{"key":"2325_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch, E. et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 34, 557\u2013565 (2016).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"2325_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch, E. et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 318, 197\u2013198 (2017).","journal-title":"JAMA"},{"key":"2325_CR17","unstructured":"International Council of Nurses. Guidelines on Advanced Practice Nursing 2020. International Council of Nurses; 2020."},{"key":"2325_CR18","doi-asserted-by":"crossref","unstructured":"Wheeler, K. J. et al. Advanced practice nursing roles, regulation, education, and practice: a global study. Ann. Glob. Health 88, 42 (2022).","DOI":"10.5334\/aogh.3698"},{"key":"2325_CR19","doi-asserted-by":"publisher","first-page":"e66275","DOI":"10.2196\/66275","volume":"27","author":"E Minvielle","year":"2025","unstructured":"Minvielle, E. et al. The effect of nurse navigators in digital remote monitoring in cancer care: case study using structural equation modeling. J. Med. Internet Res. 27, e66275 (2025).","journal-title":"J. Med. Internet Res."},{"key":"2325_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10198-024-01702-1","volume":"26","author":"E Minvielle","year":"2025","unstructured":"Minvielle, E. et al. A budget impact analysis of a digital monitoring solution in patients treated with oral anticancer agents: a medico-economic analysis of the randomized phase 3 CAPRI trial. Eur. J. Health Econ. 26, 267\u2013273 (2025).","journal-title":"Eur. J. Health Econ."},{"key":"2325_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2066-x","volume":"17","author":"C Gerv\u00e8s-Pinqui\u00e9","year":"2017","unstructured":"Gerv\u00e8s-Pinqui\u00e9, C. et al. Impacts of a navigation program based on health information technology for patients receiving oral anticancer therapy: the CAPRI randomized controlled trial. BMC Health Serv. Res 17, 133 (2017).","journal-title":"BMC Health Serv. Res"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02325-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02325-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02325-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:05:26Z","timestamp":1770779126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02325-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02325-3","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. declares conflicts related to BMS, Pfizer, Sanofi, Roche, MSD, Leo Pharma, Amgen, Pierre Fabre Oncologie, Gilead, Pharmanovia, Daiichi Sankyo, Thermo Fisher, Viatris, and GSK. M.D.P. declares conflicts related to Bayer, Sandoz, Pierre Fabre Oncologie, Astellas, Janssen, Roche, Sanofi, AMGEN, KyowaKirin, MSD, Mundipharma, Gilead, Novartis, AstraZeneca, Pfizer, Viatris. OM is an employee and shareholder of Amgen, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}